Beijing Primegene Therapeutics Co. Ltd. has divulged thioether compounds acting as transient receptor potential cation channel subfamily V member 3 (TRPV3) antagonists reported to be useful for the treatment of pain, pruritus, inflammation, fever, cystitis, irritable bowel syndrome, cough and alopecia.
Scientists at Cerevance Inc. and Cerevance Ltd. have described potassium channel subfamily K member 13 (KCNK13; THIK-1) blockers reported to be useful for the treatment of fibrosis, depression, diabetes, gout, psoriasis, atherosclerosis, inflammatory bowel disease and traumatic brain injury.
Kapoose Creek Bio Corp. has announced the identification and advancement of two lead compounds with potential in neurology, specifically for indications in neurodegeneration and mental health. The compounds, KCB-100 and KCB-200, have shown potent neuroplastic and neuroprotective activity in gold-standard tests of primary neurons.
Tetra Pharm Technologies ApS and Kvanctify ApS have entered into a strategic partnership to accelerate the identification and development of novel drug candidates targeting the endocannabinoid system.
Chinese investigators have reported that high levels of triggering receptor expressed on myeloid cells 2 (TREM2) expression, which are immunosuppressive in multiple solid tumors, were protective in glioblastoma multiforme (GBM). The findings were published May 23, 2024, in Cancer Cell.
Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), also known as PIP2, is a cellular membrane phospholipid generated by phosphatidylinositol phosphorylation that regulates the functions of several proteins.
Bristol Myers Squibb Co. has exercised its option for an exclusive global license for PRX-019, a potential treatment of neurodegenerative diseases with an undisclosed target, under an agreement with Prothena Corp. plc.
Genetic deletion of protease-activated receptor 4 (PAR4) in experimental models has been linked to improvement in neurological dysfunction and reduction of infarct volume in the context of stroke. Moreover, pretreatment with PAR4 antagonists in models of traumatic brain injury has shown protection against secondary tissue injury and thrombo-inflammatory activation.
RSS
